Gibson Dunn, Orrick and DeHeng Law Offices assisted in the Continent Pharmaceuticals (BJContinent) acquisition of Nasdaq-listed Catalyst Biosciences to achieve a backdoor listing, the first of its kind since China’s new overseas offering rules took effect in March.
BJContinent, which was acquired by Japanese corporation GNI Group in 2011, has made three unsuccessful attempts to list in Hong Kong. The new company was renamed Gyre Therapeutics, trading under the stock symbol Gyre.
Gibson acted as legal counsel to BJContinent’s parent company, GNI Group.
Orrick served as legal counsel to Catalyst Biosciences, co-led by New York-based partners Stephen Thau and David Schwartz, and Boston-based partner Albert Vanderlaan.
DeHeng advised BJContinent on domestic law, co-led by its Beijing-based partners Dong Liyang, Li Hua and Zhang Xiaodan.
